Related Experiment Video
Updated: Jul 6, 2026
10:10
Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
Platelet aggregation and recruitment with aspirin-clopidogrel therapy
Cathy M Helgason1, Enzo Grossi, Dilip Pandey
1Department of Neurology, University of Illinois College of Medicine at Chicago, Chicago, IL 60612, USA. helgason@uic.edu
Cerebrovascular Diseases (Basel, Switzerland)
|March 20, 2008
Summary
Aspirin-clopidogrel therapy enhances platelet inhibition over time in stroke patients. This combination therapy significantly reduces platelet aggregation and recruitment, suggesting improved antiplatelet effects with continued use.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Neurology
Background:
- Aspirin-clopidogrel combination therapy is known to inhibit platelet aggregation.
- The impact of this combination on platelet recruitment remains unclear.
Purpose of the Study:
- To investigate the effect of aspirin-clopidogrel combination therapy on platelet recruitment.
- To compare platelet reactivity between aspirin monotherapy and combination therapy in chronic ischemic stroke patients.
Main Methods:
- Platelet reactivity tests, including ex vivo platelet aggregation and recruitment, were performed on 30 patients over 3 months.
- Urinary 11-dehydro-thromboxane B(2) (11-dhTxB(2)) excretion was measured.
- Statistical analysis, including ANOVA and longitudinal regression, was used to compare outcomes and assess changes over time. Nonlinear mapping was employed to analyze patient-specific variable interconnections.
Main Results:
- Aspirin-clopidogrel significantly reduced adenosine-diphosphate- and collagen-induced platelet aggregation and platelet recruitment compared to aspirin alone.
- A time-dependent increase in the inhibition of platelet recruitment was observed with combination therapy.
- Urinary 11-dhTxB(2) levels did not correlate with platelet aggregation response. Patient-specific interconnections were revealed by nonlinear mapping.
Conclusions:
- Aspirin-clopidogrel combination therapy demonstrates increasing platelet inhibition over time.
- Further research is warranted to explore the clinical implications of this enhanced antiplatelet effect on vascular complications.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...